NO178789C - Fremgangsmåte for fremstilling av gamma-interferonpolypeptid med forbedret stabilitet, ekspresjonsvektor samt DNA-sekvens kodende for polypeptidene - Google Patents

Fremgangsmåte for fremstilling av gamma-interferonpolypeptid med forbedret stabilitet, ekspresjonsvektor samt DNA-sekvens kodende for polypeptidene

Info

Publication number
NO178789C
NO178789C NO845042A NO845042A NO178789C NO 178789 C NO178789 C NO 178789C NO 845042 A NO845042 A NO 845042A NO 845042 A NO845042 A NO 845042A NO 178789 C NO178789 C NO 178789C
Authority
NO
Norway
Prior art keywords
polypeptides
preparation
expression vector
sequence encoding
dna sequence
Prior art date
Application number
NO845042A
Other languages
English (en)
Norwegian (no)
Other versions
NO178789B (no
NO845042L (no
Inventor
Patrick William Gray
Ernst Heinrich Rinderknecht
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27072811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO178789(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO845042L publication Critical patent/NO845042L/no
Publication of NO178789B publication Critical patent/NO178789B/no
Publication of NO178789C publication Critical patent/NO178789C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/30—Signal or leader sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
NO845042A 1983-12-16 1984-12-14 Fremgangsmåte for fremstilling av gamma-interferonpolypeptid med forbedret stabilitet, ekspresjonsvektor samt DNA-sekvens kodende for polypeptidene NO178789C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56200983A 1983-12-16 1983-12-16
US06/584,217 US4855238A (en) 1983-12-16 1984-02-27 Recombinant gamma interferons having enhanced stability and methods therefor

Publications (3)

Publication Number Publication Date
NO845042L NO845042L (no) 1985-06-17
NO178789B NO178789B (no) 1996-02-26
NO178789C true NO178789C (no) 1996-06-05

Family

ID=27072811

Family Applications (1)

Application Number Title Priority Date Filing Date
NO845042A NO178789C (no) 1983-12-16 1984-12-14 Fremgangsmåte for fremstilling av gamma-interferonpolypeptid med forbedret stabilitet, ekspresjonsvektor samt DNA-sekvens kodende for polypeptidene

Country Status (23)

Country Link
US (4) US4855238A (ja)
EP (1) EP0146354B2 (ja)
JP (6) JPH0789935B2 (ja)
KR (1) KR940008978B1 (ja)
AT (1) ATE135405T1 (ja)
AU (1) AU597872B2 (ja)
CA (1) CA1341573C (ja)
CY (1) CY1945A (ja)
DE (1) DE3486424T3 (ja)
DK (1) DK166832B1 (ja)
ES (1) ES8801553A1 (ja)
FI (1) FI91884C (ja)
GR (1) GR82468B (ja)
HK (1) HK175996A (ja)
HU (1) HU202278B (ja)
IE (1) IE72494B1 (ja)
IL (1) IL73803A (ja)
LV (1) LV11633B (ja)
MY (1) MY102899A (ja)
NO (1) NO178789C (ja)
OA (1) OA07902A (ja)
PH (1) PH24790A (ja)
PT (1) PT79691A (ja)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58110548A (ja) * 1981-12-24 1983-07-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチド
GB8406910D0 (en) * 1984-03-16 1984-04-18 Biogen Nv Gamma interferon
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
ZA846554B (en) * 1983-09-20 1985-04-24 Hoffmann La Roche Immune interferon and method for its purification
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
MX9203641A (es) * 1983-12-16 1992-07-01 Genentech Inc Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion.
JPS60172999A (ja) * 1983-12-20 1985-09-06 Suntory Ltd 新規な塩基性ポリペプチドおよびその製造法
DK168016B1 (da) * 1983-12-26 1994-01-17 Kyowa Hakko Kogyo Kk Derivat af humant interferon-gamma-polypeptid
EP0174999B1 (en) * 1984-03-16 1991-04-17 Biogen, Inc. Method for improving expression and method thereto
DE3414831A1 (de) * 1984-04-19 1985-10-31 Hoechst Ag, 6230 Frankfurt Herstellung von polypeptiden mit human-gammainterferon-aktivitaet
IL75302A0 (en) * 1984-06-06 1985-09-29 Takeda Chemical Industries Ltd Novel polypeptide and production thereof
CA1302320C (en) * 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
JPS61108397A (ja) * 1984-10-31 1986-05-27 Green Cross Corp:The インタ−フエロン−γ蛋白質の製造法
JPS6156195A (ja) * 1985-03-01 1986-03-20 Asahi Chem Ind Co Ltd 新規生理活性ペプチド
US4873312A (en) * 1985-04-25 1989-10-10 Amgen Method for purifying interferon and composition of matter produced thereby
ATE81675T1 (de) * 1985-04-30 1992-11-15 Takeda Chemical Industries Ltd Produktion eines proteins.
DE3532134A1 (de) * 1985-09-10 1987-03-12 Basf Ag Verfahren zur herstellung von proteinen bestimmter n-terminaler struktur mit hilfe von prokaryonten
DE3536939A1 (de) * 1985-10-17 1987-04-23 Hoechst Ag Biologisch aktive derivate des human-(gamma)-interferons, ihre herstellung und arzneimittel, die solche derivate enthalten
DE3751664T2 (de) * 1986-08-01 1996-06-05 Commw Scient Ind Res Org Rekombinanter impfstoff
GB8619725D0 (en) * 1986-08-13 1986-09-24 Hoffmann La Roche Homogenous interferon fragments
US5157004A (en) * 1986-12-27 1992-10-20 Takeda Chemical Industries, Ltd. Polypeptides and production thereof
JP2653061B2 (ja) * 1986-12-27 1997-09-10 武田薬品工業株式会社 新規ポリペプチドおよびその製造法
DE3730331A1 (de) * 1987-09-10 1989-03-30 Basf Ag Neue polypeptide, verfahren zur herstellung, die vektoren dafuer und arzneimittel daraus
AT393690B (de) * 1987-10-08 1991-11-25 Hoffmann La Roche Homogene, rekombinante immun-interferonfragmente
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
ATE198353T1 (de) * 1988-08-24 2001-01-15 American Cyanamid Co Stabilisierung von somatotropinen durch modifikation von cystein-resten durch orts- spezifische mutagenese oder chemische derivatisierung
US5198212A (en) * 1988-10-31 1993-03-30 University Of Lousville Research Foundation Incorporated Method and compositions for treatment of trauma-associated sepsis with gamma interferon
US6068994A (en) * 1989-08-07 2000-05-30 Chiron Corporation Ubiquitin expression system
BG52073B2 (en) * 1990-01-24 1996-04-30 Inst Molekuljarna Biolog Method for the preparation of recombinant human noncystein -interferon, free of n-end methionine
DE69104619T2 (de) * 1990-08-31 1995-04-13 Schering Corp Verwendungsmethoden von humanem Gammainterferon 4-134.
DE4036856C1 (ja) * 1990-11-19 1992-05-27 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung Ev, 8000 Muenchen, De
US5227158A (en) * 1991-06-10 1993-07-13 Genentech, Inc. Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5328989A (en) * 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
CA2165666A1 (en) * 1993-07-01 1995-01-12 Hugh George Culture medium for recombinant yeasts
TW249202B (ja) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
ATE375363T1 (de) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
JP5030329B2 (ja) 1998-04-02 2012-09-19 ジェネンテック， インコーポレイテッド 心臓肥大の処置
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
RU2140285C1 (ru) * 1999-01-25 1999-10-27 Гапонюк Петр Яковлевич Противовирусное средство - капли в нос "гриппферон"
US6475796B1 (en) * 1999-05-20 2002-11-05 Scios, Inc. Vascular endothelial growth factor variants
CA2374050A1 (en) * 1999-05-20 2000-11-30 Scios Inc. Vascular endothelial growth factor dimers
SK8292002A3 (en) * 1999-11-12 2002-12-03 Maxygen Holdings Ltd A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof
CN1309423C (zh) 1999-11-12 2007-04-11 马克西根控股公司 干扰素γ偶联物
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
IL152804A0 (en) * 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
AU2587002A (en) * 2000-11-03 2002-05-15 Biomedicines Inc Method for short-term and long-term drug dosimetry
BR0206364A (pt) * 2001-01-09 2005-08-16 Baylor Res Inst Métodos para tratar doenças auto-imunes em um indivìduo e testes diagnósticos in vitro
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US20050002900A1 (en) * 2001-11-06 2005-01-06 Grace Wong Method of treating estrogen responsive breast cancer
US20050079156A1 (en) * 2001-11-06 2005-04-14 Grace Wong Method of treating endometreosis
IL161889A0 (en) * 2001-11-09 2005-11-20 Biomedicines Inc Method for treating diseases with omega interferon
JP2005517648A (ja) * 2001-12-07 2005-06-16 インターミューン インコーポレイテッド 肝炎ウイルス感染症を治療するための組成物および方法
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
AU2003239774A1 (en) * 2002-07-03 2004-01-23 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CN101039957A (zh) 2003-05-16 2007-09-19 因特缪恩公司 合成的趋化因子受体配体及其使用方法
US20070092488A1 (en) * 2003-05-16 2007-04-26 Intermune Inc. Methods of treating idiopathic pulmonary fibrosis
HRP20130098T1 (hr) 2003-10-14 2013-02-28 F. Hoffmann - La Roche Ag MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
EP2327724A3 (en) 2004-02-02 2011-07-27 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2006141263A (ja) * 2004-11-18 2006-06-08 Kyoto Univ （ｒ）−ヒドロキシニトリルリアーゼの製造方法
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP1877434A2 (en) * 2005-05-04 2008-01-16 Nautilus Biotech Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP2049081B1 (en) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
PT2468300T (pt) 2006-09-26 2018-01-30 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8617531B2 (en) 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
HRP20130259T1 (hr) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
MX2009011870A (es) 2007-05-02 2009-11-12 Ambrx Inc Polipeptidos de interferon beta modificados y usos de los mismos.
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
US8243103B2 (en) * 2009-05-29 2012-08-14 Exelis, Inc. Laser aiming spot distinguishing methods and apparatus
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
CA2788607C (en) * 2010-02-01 2018-03-20 Digna Biotech,S.L. Process for the production of interferon alpha 5
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
KR102136433B1 (ko) 2012-05-16 2020-07-22 이뮨 디자인 코포레이션 Hsv-2 백신
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
EP2986303B1 (en) 2013-04-18 2020-02-26 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
DK3458475T3 (da) 2016-05-16 2022-09-12 Access To Advanced Health Inst Formulering, der indeholder tlr-agonist, og anvendelsesfremgangsmåder
AU2017273650B2 (en) 2016-06-01 2022-08-18 Access To Advanced Health Institute Nanoalum particles containing a sizing agent
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CA3040802A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
US11672877B2 (en) 2017-08-23 2023-06-13 Wayne State University In vivo immunoimaging of interferon-gamma
CA3078223A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
AU2021237818A1 (en) 2020-03-19 2022-09-29 Ferring Ventures Ltd. Temperature-responsive virus storage system
TW202203962A (zh) 2020-03-30 2022-02-01 英商崔澤爾有限公司 用於治療癌症之組合物及方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7404589A (nl) * 1974-04-03 1975-10-07 Stichting Rega V Z W Werkwijze voor het stabiliseren van interferon.
NL7404590A (nl) * 1974-04-03 1975-10-07 Stichting Rega V Z W Werkwijze voor het reactiveren van interferon.
US4332892A (en) * 1979-01-15 1982-06-01 President And Fellows Of Harvard College Protein synthesis
JPS5598118A (en) * 1979-01-18 1980-07-25 Hayashibara Takeshi Preparation of type-2 interferon and drug containing the same
AU538665B2 (en) * 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
IL58765A (en) * 1979-11-21 1986-09-30 Yeda Res & Dev Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta
GB2068970B (en) * 1980-02-06 1983-06-22 Searle & Co Recombinant dna technique for the preparation of a protein resembling human interferon
DE3005897A1 (de) * 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4460685A (en) * 1980-05-29 1984-07-17 New York University Method of enhancing the production of human γ Interferon
US4311639A (en) * 1980-07-25 1982-01-19 E. I. Du Pont De Nemours And Company Immunogenic interferon peptides
US4341761A (en) * 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
FI64813C (fi) * 1980-12-31 1984-01-10 Ilkka Antero Palva Foerfarande foer producering av ett utvalt aeggviteaemne och vid foerfarandet anvaenda rekombinantplasmidvektorer
US4382027A (en) * 1981-08-18 1983-05-03 Meloy Laboratories, Inc. Purification of human immune interferon
IL65475A0 (en) * 1981-04-17 1982-07-30 Meloy Lab Production of immune interferon and its mrna
US4404188A (en) * 1981-07-29 1983-09-13 Massachusetts General Hospital Purified Mullerian Inhibiting Substance and method of purification
US5096705A (en) * 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
AU561343B2 (en) * 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5582824A (en) * 1981-10-19 1996-12-10 Genentech, Inc. Recombinant DES-CYS-TYR-CYS human immune interferon
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
JPS58110548A (ja) * 1981-12-24 1983-07-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチド
US4388234A (en) * 1981-12-28 1983-06-14 Hoffmann-La Roche Inc. Peptide isolation
EP0088540A3 (en) * 1982-02-22 1984-10-17 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing human immune interferon-like polypeptides
US5004689A (en) * 1982-02-22 1991-04-02 Biogen, Massachusetts DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields
ZA83768B (en) * 1982-03-01 1983-10-26 Hoffmann La Roche Homogeneous human immune interferon and process therefor
IL68100A0 (en) * 1982-03-24 1983-06-15 Takeda Chemical Industries Ltd Novel dna and use thereof
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JPH0787797B2 (ja) * 1982-05-20 1995-09-27 サントリー株式会社 ヒト・ガンマ・インタ−フエロン様ポリペプチドの製造法
US4681848A (en) * 1982-09-22 1987-07-21 Takeda Chemical Industries, Ltd. Novel peptide and use thereof
IL69851A0 (en) * 1982-09-30 1983-12-30 Japan Found Cancer Novel dna and recombinant plasmid containing the same
WO1984002129A1 (fr) * 1982-11-22 1984-06-07 Takeda Chemical Industries Ltd Proteine de l'interferon immun humain et son procede de preparation
US4432895A (en) * 1982-11-24 1984-02-21 Hoffmann-La Roche Inc. Monomeric interferons
US4485017A (en) * 1982-12-22 1984-11-27 Cetus Corporation Isolation of human interferon by immunosorbent and high performance liquid chromatography
JPH0740925B2 (ja) 1983-03-14 1995-05-10 協和醗酵工業株式会社 新規ヒトインタ−フエロン−γポリペプチド
JPS59169494A (ja) * 1983-03-17 1984-09-25 Takeda Chem Ind Ltd 新規組み換えｄｎａおよびその用途
US4599306A (en) * 1983-04-15 1986-07-08 Amgen Monoclonal antibodies which specifically bind to human immune interferon
ZA844082B (en) * 1983-06-01 1985-09-25 Hoffmann La Roche Polypeptides having interferon activity
IL72773A0 (en) * 1983-08-29 1984-11-30 Meloy Lab Production of immune interferon and its mrna
US4681930A (en) * 1983-09-20 1987-07-21 Hoffmann-La Roche Inc. Immune interferon and a method for its extraction and purification
US4476049A (en) * 1983-09-20 1984-10-09 Hoffmann-La Roche Inc. Method for the extraction of immune interferon
US4604284A (en) * 1983-09-20 1986-08-05 Hoffmann-La Roche Inc. Homogeneous immune interferon fragment
JPS6079000A (ja) * 1983-10-04 1985-05-04 Takeda Chem Ind Ltd ヒトγ型インタ−フエロン単量体の製造法
JPH0788398B2 (ja) * 1983-10-17 1995-09-27 サントリー株式会社 新規生理活性ポリペプチドおよびその製造法
JPS60118196A (ja) * 1983-11-30 1985-06-25 Takeda Chem Ind Ltd インタ−フェロンの製造法
FR2556365B1 (fr) * 1983-12-09 1987-07-31 Transgene Sa Vecteurs de clonage et d'expression de l'interferon-g, bacteries transformees et procede de preparation de l'interferon-g
MX9203641A (es) * 1983-12-16 1992-07-01 Genentech Inc Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion.
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
IL75302A0 (en) * 1984-06-06 1985-09-29 Takeda Chemical Industries Ltd Novel polypeptide and production thereof
JP2653061B2 (ja) 1986-12-27 1997-09-10 武田薬品工業株式会社 新規ポリペプチドおよびその製造法

Also Published As

Publication number Publication date
EP0146354A3 (en) 1986-03-19
US6497871B1 (en) 2002-12-24
AU3663584A (en) 1985-06-20
DE3486424T3 (de) 2002-06-06
JPH0789935B2 (ja) 1995-10-04
JP2545206B2 (ja) 1996-10-16
ES538620A0 (es) 1988-02-16
JPS60202899A (ja) 1985-10-14
IE72494B1 (en) 1997-04-23
HU202278B (en) 1991-02-28
MY102899A (en) 1993-03-31
JPH08151399A (ja) 1996-06-11
ATE135405T1 (de) 1996-03-15
HUT36187A (en) 1985-08-28
US5574137A (en) 1996-11-12
CY1945A (en) 1984-12-14
AU597872B2 (en) 1990-06-14
EP0146354B2 (en) 2001-10-24
FI91884C (fi) 1994-08-25
US4855238A (en) 1989-08-08
JPH07173196A (ja) 1995-07-11
LV11633A (lv) 1996-12-20
JP2886145B2 (ja) 1999-04-26
DE3486424D1 (de) 1996-04-18
DK600984A (da) 1985-08-22
OA07902A (en) 1986-11-20
LV11633B (en) 1997-08-20
JPH03201979A (ja) 1991-09-03
US5595888A (en) 1997-01-21
EP0146354A2 (en) 1985-06-26
DE3486424T2 (de) 1996-09-12
JPH0794477B2 (ja) 1995-10-11
JPH0919295A (ja) 1997-01-21
FI91884B (fi) 1994-05-13
ES8801553A1 (es) 1988-02-16
JP2580491B2 (ja) 1997-02-12
IE843203L (en) 1985-06-16
GR82468B (en) 1985-03-27
FI844934A0 (fi) 1984-12-13
DK600984D0 (da) 1984-12-14
KR850004273A (ko) 1985-07-11
HK175996A (en) 1996-09-27
NO178789B (no) 1996-02-26
NO845042L (no) 1985-06-17
KR940008978B1 (ko) 1994-09-28
JP2719128B2 (ja) 1998-02-25
PH24790A (en) 1990-10-30
DK166832B1 (da) 1993-07-19
CA1341573C (en) 2008-05-13
PT79691A (en) 1985-01-01
EP0146354B1 (en) 1996-03-13
JPH10210985A (ja) 1998-08-11
FI844934L (fi) 1985-06-17
IL73803A (en) 1997-09-30
IL73803A0 (en) 1985-03-31

Similar Documents

Publication Publication Date Title
NO178789C (no) Fremgangsmåte for fremstilling av gamma-interferonpolypeptid med forbedret stabilitet, ekspresjonsvektor samt DNA-sekvens kodende for polypeptidene
LU88327I2 (fr) Interferon gamma-1b (Imukin /Immukine)
FI863044A0 (fi) Foerfarande foer framstaellning av erythropoietin.
DK105892A (da) Dna-sekvens, der koder for et modificeret human-beta-interferonprotein (ifn-beta), hvori 17-cysteinresten er udeladt eller udskiftet med en anden aminosyrerest, ekspressionsvektor indeholdende dna-sekvensen, vaertcelle eller -organisme transformeret med ekspressionsvektoren samt fremgangsmaade til fremstilling af det modificerede protein.
NO20011861L (no) Interferon-<beta> fusjonsproteiner samt anvendelse derav
ATE44652T1 (de) Zubereitung mit gehalt an stabilisiertes polypeptid mit gamma-interferon aktivitaet.
ATE46348T1 (de) Neue, physiologisch aktive polypeptide und deren herstellungsverfahren.

Legal Events

Date Code Title Description
MK1K Patent expired